Close Asset Management Ltd Has $4.93 Million Holdings in Pfizer Inc. (NYSE:PFE)

Close Asset Management Ltd reduced its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 9.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 194,437 shares of the biopharmaceutical company's stock after selling 20,747 shares during the period. Close Asset Management Ltd's holdings in Pfizer were worth $4,926,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Clarity Asset Management Inc. bought a new stake in Pfizer in the fourth quarter valued at about $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. North Capital Inc. acquired a new position in Pfizer during the first quarter valued at approximately $28,000. Bernard Wealth Management Corp. acquired a new position in Pfizer during the fourth quarter valued at approximately $30,000. Finally, Horizon Financial Services LLC acquired a new position in Pfizer during the first quarter valued at approximately $35,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 3.6%

Shares of Pfizer stock opened at $25.13 on Wednesday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The company's fifty day moving average price is $24.07 and its two-hundred day moving average price is $24.71. The firm has a market capitalization of $142.84 billion, a PE ratio of 18.21, a price-to-earnings-growth ratio of 0.88 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company's revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.82 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.85%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is 124.64%.

Analyst Upgrades and Downgrades

A number of research firms have commented on PFE. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. TD Cowen decreased their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Finally, Citigroup boosted their price objective on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.